The Society for Immunotherapy of Cancer (SITC) is set to host the EU Immuno-oncology Drug Development Summit in Lausanne, Switzerland, on September 3–4, 2026. This event aims to unite key players in the immuno-oncology field, including regulatory bodies, biotech firms, and academic researchers, to enhance collaboration and share best practices in drug development.
The summit will feature a keynote address by Dr. E. John Wherry, focusing on the intersection of immuno-oncology and autoimmunity. Organizers, including Pedro Romero from Novigenix, emphasize the need for collective efforts to expedite the development of new therapeutics for cancer patients. The event is supported by notable partners such as the Swiss Biotech Association and the Association for Cancer Immunotherapy (CIMT).
Attendees will have the opportunity to engage in discussions on optimal clinical trial design specific to immuno-oncology, explore resources for advancing therapies beyond established pathways, and network with professionals from across Europe and the United States. This summit represents a significant step in fostering international collaboration and innovation in cancer treatment.
This initiative reflects the growing recognition of immuno-oncology's potential in transforming cancer care. As the field continues to evolve, such gatherings are crucial for driving forward the development of effective therapies that could ultimately improve patient outcomes.